Inferra AI / Company / IART
Integra Lifesciences Holdings Corp
IART · Health Care
Last earnings Oct 21, 2026
Key results
Revenuequarter
$402.1 million
Third Quarter 2025 Highlights Third quarter revenues of $402.1 million increased 5.6% on a reported basis and 5.0% on an organic basis compared to the prior year.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Third Quarter 2025 Consolidated Performance Total reported revenues of $402.1 million increased 5.6% on a reported basis and 5.0% on an organic basis compared to the prior year.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
GAAP gross marginquarter
51.5%
The Company reported GAAP gross margin of 51.5%, compared to 52.6% in the third quarter of 2024.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Adjusted gross marginquarter
62.9%
Adjusted gross margin was 62.9%, compared to 63.0% in the prior year.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Adjusted net incomequarter
$41.6 million
Adjusted net income for the third quarter of 2025 was $41.6 million, or $0.54 per diluted share, compared to $31.7 million, or $0.41 per diluted share, in the prior year.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Total revenuequarter
$292.6 million
Third Quarter 2025 Segment Performance Codman Specialty Surgical ( 70% of Revenues) Total revenues were $292.6 million, representing reported growth of 8.1% and organic growth of 7.1% compared to the third quarter of 2024.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Revenues) Total revenues were $109.5 million, representing a reported decline of (0.5)% and organic decline of (0.3)% compared to the third quarter of 2024.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
The revenue range represents reported growth of 0.6% to 1.8% and organic growth of (1.6%) to (0.4%).
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
AI analysis
Q3 2025 · reported Oct 30, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
GAAP gross margin
Percent of revenue, as stated
EX-99 · Oct 30, 2025 Margin values as stated in the release.
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · Oct 30, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q3 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $402.1 million | — | — |
| GAAP gross margin | 51.5% | — | 52.6% |
| Adjusted gross margin | 62.9% | — | 63.0% |
| Adjusted net income | $41.6 million | — | — |
| Total revenue | $292.6 million | — | — |
Guidance · company-stated
“in a range of $0.79 to $0.84”
Guidance stated in the release's Business Outlook table for the fourth quarter; no direction stated — figures as stated in the table.
Margin
Capital allocation
Total balance sheet debt and net debt at the end of the quarter were $1.8 billion and $1.6 billion, respectively, and the consolidated total leverage ratio was 4.3 x.
As of the end of the quarter, the Company had total liquidity of approximately $549.8 million, including $267.9 million in cash plus short-term investments and the remainder available under its revolving credit facility.
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue +302.9% computed from stated figures
Event summary
Third quarter GAAP earnings per diluted share of $(0.07), compared to $(0.14) in the prior year
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
adjusted EPS: “adjusted EPS in a range of $0.79 to $0.84”
revenue: “revenue guidance range to $1.620 billion to $1.640 billion”
adjusted EPS (“the fourth quarter”)
“adjusted EPS in a range of $0.79 to $0.84”
revenue (“the fourth quarter”)
“revenue guidance range to $1.620 billion to $1.640 billion”
Guidance stated in the release's Business Outlook table for the fourth quarter; no direction stated — figures as stated in the table.
Capital allocation
Total balance sheet debt and net debt at the end of the quarter were $1.8 billion and $1.6 billion, respectively, and the consolidated total leverage ratio was 4.3 x.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
As of the end of the quarter, the Company had total liquidity of approximately $549.8 million, including $267.9 million in cash plus short-term investments and the remainder available under its revolving credit facility.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
and international governmental, regulatory, fiscal, monetary and public health responses to any future public health crises fluctuations in foreign currency exchange rates the amount of our bank borrowings outstanding and other factors influencing liquidity potential negative impacts resulting from environmental, social and governance matters and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading Risk Factors included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2024 and information contained in subsequent filings with the Securities and Exchange Commission.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Discussion of Adjusted Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ( EBITDA ), adjusted net income, adjusted gross margin, adjusted earnings per diluted share, and net debt.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
The measure of net debt consists of GAAP total debt (excluding deferred financing costs) less short-term investments, cash and cash equivalents.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Reconciliations of GAAP revenues to organic revenues, GAAP net income to adjusted EBITDA, and adjusted net income, GAAP gross margin to adjusted gross margin, GAAP total debt to net debt, and GAAP earnings per diluted share to adjusted earnings per diluted share all for the quarters ended September 30, 2025 and 2024.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Strategy & priorities
Relaunch of PriMatrix and Durepair ahead of schedule, through dual sourcing supply strategy.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
We are making progress in implementing our comprehensive plan to systematically strengthen the entirety of our supply chain and quality management system, and we remain confident in our strategy to improve overall performance and drive the Company s transformation.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
In November 2025, the FASB issued ASU 2025-09, Derivatives and Hedging (Topic 815): Hedge Accounting Improvements ( ASU 2025-09 ), which amends existing guidance to clarify and enhance the hedge accounting guidance in FASB Topic 815 and better align hedge accounting with the economics of an entity s risk management strategies to enable entities to achieve and maintain hedge accounting for highly effective economic hedges.
SEC original ↗Integra Lifesciences Holdings Corp — 10-Q Quarterly report10-QOct 23, 2026
In addition, during the first quarter of 2026, the Company renamed its Codman Specialty Surgical reportable segment to Specialty Surgery and its Tissue Technologies reportable segment to Tissue Reconstruction to better align with the reportable segments business activities, structures, and strategies.
SEC original ↗Integra Lifesciences Holdings Corp — 10-Q Quarterly report10-QOct 23, 2026
Significant Estimates Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company s strategic partners.
SEC original ↗Integra Lifesciences Holdings Corp — 10-Q Quarterly report10-QOct 23, 2026
Risks & headwinds
Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Such risks and uncertainties include, but are not limited, to the following the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, inflation, supply chain disruptions, trade regulation and tariffs, duties or other measures implemented by the U.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
and international governmental, regulatory, fiscal, monetary and public health responses to any future public health crises fluctuations in foreign currency exchange rates the amount of our bank borrowings outstanding and other factors influencing liquidity potential negative impacts resulting from environmental, social and governance matters and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading Risk Factors included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2024 and information contained in subsequent filings with the Securities and Exchange Commission.
SEC original ↗Integra Lifesciences Holdings Corp — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Legal Proceedings 52 Item 1A.
SEC original ↗Integra Lifesciences Holdings Corp — 10-Q Quarterly report10-QOct 23, 2026
IEEPA tariff refund receivable In February 2026, the U.
SEC original ↗Integra Lifesciences Holdings Corp — 10-Q Quarterly report10-QOct 23, 2026
administration s tariff program implemented during 2025 under the International Emergency Economic Powers Act ( IEEPA ), concluding that IEEPA did not authorize the broad import duties previously imposed.
SEC original ↗Integra Lifesciences Holdings Corp — 10-Q Quarterly report10-QOct 23, 2026
Earnings deck slides
0 decks with slide viewIntegra Lifesciences Holdings Corp — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
31 documentsEarnings releases
12 documentsPresentations
1 document- Q2 2026
- IARTDeck
Transcripts
0 documentsNo transcripts for Integra Lifesciences Holdings Corp are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.